These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1378111)

  • 1. Mechanism of antiarrhythmic efficacy of propafenone as assessed by programmed electrical stimulation in conscious dogs.
    Todt H; Krumpl G; Krejcy K; Raberger G
    J Cardiovasc Pharmacol; 1992 Mar; 19(3):341-8. PubMed ID: 1378111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lidocaine has a narrow antiarrhythmic dose range against ventricular arrhythmias induced by programmed electrical stimulation in conscious postinfarction dogs.
    Krejcy K; Krumpl G; Todt H; Raberger G
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Aug; 346(2):213-8. PubMed ID: 1448183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ajmaline on sustained ventricular tachycardia induced by programmed electrical stimulation in conscious dogs after myocardial infarction.
    Todt H; Krumpl G; Zojer N; Krejcy K; Raberger G
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Sep; 348(3):290-7. PubMed ID: 7694159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.
    Winslow E; Campbell JK; Barron E; Marshall RJ; Muir AW
    Br J Pharmacol; 1991 Dec; 104(4):853-8. PubMed ID: 1810599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation.
    Doherty JU; Waxman HL; Kienzle MG; Cassidy DM; Marchlinski FE; Buxton AE; Josephson ME
    J Am Coll Cardiol; 1984 Aug; 4(2):378-81. PubMed ID: 6736479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects.
    Kirchhof PF; Fabritz CL; Franz MR
    Circulation; 1998 Jun; 97(25):2567-74. PubMed ID: 9657478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
    Black SC; Butterfield JL; Lucchesi BR
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):810-8. PubMed ID: 7509898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart.
    Fazekas T; Carlsson L; Scherlag BJ; Mabo P; Poty H; Palmer M; Patterson E; Berlin KD; Garrison GL; Lazzara R
    J Cardiovasc Pharmacol; 1996 Aug; 28(2):182-91. PubMed ID: 8856472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide.
    Karagueuzian HS; Sugi K; Ohta M; Meesmann M; Ino T; Peter T; Mandel WJ
    Am Heart J; 1986 Dec; 112(6):1173-83. PubMed ID: 3788764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia.
    Shen EN; Sung RJ; Morady F; Schwartz AB; Scheinman MM; DiCarlo L; Shapiro W
    J Am Coll Cardiol; 1984 May; 3(5):1291-7. PubMed ID: 6707382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the antiarrhythmic profile of the new class I agent diprafenone.
    Gülker H; Thale J; Olbing B; Heuer H; Frenking B; Bender F
    Arzneimittelforschung; 1985; 35(9):1387-93. PubMed ID: 4084340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: a comparative study with dobutamine.
    Ozaki T; Uematsu T; Nagashima S; Nishimoto M; Nakashima M
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):478-87. PubMed ID: 1766473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
    Drexler AP; Micklas JM; Brooks RR
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic effects of oral propafenone in Wolff-Parkinson-White syndrome studied by programmed electrical stimulation.
    Sethi KK; Prasad GS; Mohan JC; Arora R; Khalilullah M
    Indian Heart J; 1991; 43(1):5-10. PubMed ID: 1894303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent.
    Black SC; Chi LG; Mu DX; Lucchesi BR
    J Pharmacol Exp Ther; 1991 Aug; 258(2):416-23. PubMed ID: 1865349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion.
    Aidonidis I; Brachmann J; Rizos I; Zacharoulis A; Stavridis I; Toutouzas P; Kübler W
    Cardiovasc Drugs Ther; 1995 Aug; 9(4):555-63. PubMed ID: 8547205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia.
    Chilson DA; Heger JJ; Zipes DP; Browne KF; Prystowsky EN
    J Am Coll Cardiol; 1985 Jun; 5(6):1407-13. PubMed ID: 3889099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidysrhythmic actions of meobentine sulfate.
    Zimmerman JM; Patterson E; Pitt B; Lucchesi B
    Am Heart J; 1984 Jun; 107(6):1117-24. PubMed ID: 6720538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of propafenone in preventing ventricular tachycardia: inverse correlation with rate-related prolongation of conduction time.
    Kus T; Dubuc M; Lambert C; Shenasa M
    J Am Coll Cardiol; 1990 Nov; 16(5):1229-37. PubMed ID: 2229772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
    Wang J; Bourne GW; Wang Z; Villemaire C; Talajic M; Nattel S
    Circulation; 1993 Sep; 88(3):1030-44. PubMed ID: 8353865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.